7 RESULTS
COMMENT The NIA-AA 2018 framework for Alzheimer’s disease changed scope and now has the ambition to provide a research-only framework, with the explicit disclaimer that it should not be seen as criteria for clinical use. The authors did a great job in reviewing ...
COMMENT The U.K. Biobank will be a tremendous resource for studies on neurodegeneration, both for data discovery and for replication. In addition, it will be a useful reference set for single-subject imaging markers. We have not used the data set ourselves, but ...
COMMENT One remarkable finding of this interesting study is the observation that the CSF Aβ1-42 abnormality index only increases to 30 percent at the late AD stage. However, amyloid PET binding (which correlates around 0.8 with CSF Aβ1-42 in ADNI [Toledo et al., ...
COMMENT Ayton et al. published interesting data on CSF ferritin as a biomarker for AD. Based on the cognitive data, the authors conclude that ferritin is a trait marker because it correlates cross-sectionally with cognitive scores, but not with change in ...
COMMENT The SD (or z-score) approach mentioned by Paul Maruff and applied in the AIBL data is indeed useful to compare change on different diagnostic modalities. We have recently applied this approach in ADNI-1 data (Bertens et al., 2014). In prodromal AD we ...
COMMENT The observation that bapineuzumab lowers CSF phospho-tau (p-tau) levels is intriguing. It is consistent with the finding from the AN1792 study that immunization with aggregated β amyloid is associated with a reduction of CSF total tau levels (1). Both p ...
COMMENT Reisa Sperling and colleagues have written a thoughtful commentary on the future of trials in AD. They describe the pros and cons of primary, secondary, and tertiary prevention trials and conclude that secondary prevention trials (i.e., prevention of ...
